Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

FDA Approves Autolus’s CAR-T Therapy Aucatzyl for Relapsed or Refractory B-ALL in Adults

Biosimilars: Expanding Access to Precision Medicine through Affordable Biologic Therapies

IDEAYA Biosciences Secures Exclusive Worldwide License for Biocytogen’s BsADC Program IDE034 for Solid Tumor Treatment

Seer and Thermo Fisher Scientific Announce Strategic Collaboration to Advance Proteomics with Integrated Platform Solution

SystImmune Secures FDA Clearance for IND Application of Novel ADC Therapy BL-M17D1 for Advanced Solid Tumors

Medicare Expands Coverage for Adaptive Biotechnologies' clonoSEQ® MRD Test to Include Mantle Cell Lymphoma

Illumina and PHASE Partner to Advance Oncology Testing in the Greater Bay Area, Supporting the "Healthy China" Initiative

MGI Partners with Human Cell Atlas to Advance Global Human Cell Mapping

NHS Wales and Illumina Expand Partnership to Advance Genomic Cancer Detection and Personalized Medicine

Unlocking Genomic Potential for Rare Cancers: Cancer52 and Genomics England’s Collaborative Approach

Tempus AI Launches Immune Profile Score to Enhance Precision in Immunotherapy for Advanced Cancer Patients

Key Resources and Organizations for Precision Medicine Guidelines

MedGenome Strengthens Leadership Team to Drive North American Expansion in Precision Medicine

NCCN Expands Clinical Practice Guidelines for High-Risk Genetic Cancer Assessment

Home
/
update
/
details

Immuneel Therapeutics Appoints Amit Mookim as New CEO

NextEdge Admin

17 Sep 2024

2 min 15 sec

Chief Executive Officer,immunotherapy,Leadership

Immuneel Therapeutics is pleased to announce the appointment of Amit Mookim as Chief Executive Officer. With over 20 years of experience across life sciences, technology, and private equity, Amit is set to lead the next phase of growth and innovation for Immuneel in the cell and gene therapy space.

Amit joins Immuneel from IQVIA, where he served as Managing Director for South Asia, leading a team of over 20,000 professionals and driving significant commercial growth. Previously, he headed healthcare at KPMG India, where he helped establish and expand the firm’s healthcare practice, advising hospitals, private equity funds, and global healthcare companies.

A recognized thought leader, Amit has advised the National Health Authority on startup market access under the PMJAY scheme and worked with industry organizations like the Indian Pharmaceutical Alliance, APACMED, and FICCI. He has also contributed to leadership initiatives on universal healthcare, innovation, and regulatory collaborations across South Asia, APAC, the Middle East, and Europe.

Under his leadership, Immuneel will focus on expanding access to its CAR-T therapies, building global partnerships, and enhancing its presence in India and internationally. Co-founders Dr. Kiran Mazumdar-Shaw, Dr. Siddhartha Mukherjee, and Dr. Kush Parmar are confident in Amit’s ability to guide the company’s mission of transforming cancer care.

The Immuneel team welcomes Amit as they continue to break new ground in cancer immunotherapy for patients in India and beyond.